<DOC>
	<DOCNO>NCT00186420</DOCNO>
	<brief_summary>The purpose study evaluate time progression ( TTP ) PSA patient high risk prostate cancer definitive therapy .</brief_summary>
	<brief_title>Adjuvant Taxotere Patients With High Risk Prostate Cancer Post Prostatectomy Radiation</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Patients undergone radical prostatectomy ( unmeasurable PSA ) radiation therapy prostate cancer high risk disease define one following : Node positive disease postoperatively Capsule involvement Seminal Vesicles involvement Gleason score ≥ 8 &gt; 50 % core biopsy positive Clinical Stage T2c T3 Preop PSA &gt; 15 plus Gleason score 7 Age great 18 ECOG Performance Status 01 Serum creatinine &lt; = 1.5 mg/dl Granulocyte count &gt; = 1500/m3 , Hemoglobin &gt; 8.0 g/dl , platelet count &gt; = 100,000/m3 Total bilirubin &lt; = ULN AST , ALT Alkaline Phosphatase must within range allow eligibility . Signed patient inform consent . Men childbearing potential must willing consent use effective contraception treatment three month thereafter . Peripheral neuropathy &gt; grade 1 History severe hypersensitivity Taxotere® drug formulate polysorbate 80 . Patients receive previous chemotherapy treat another clinical trial use investigational agent . Active infection within 14 day begin treatment Patients serious illness medical condition , history significant neurologic psychiatric active infection . Patients current malignancy . Patients prior history situ lobular carcinoma breast , basal squamous cell skin cancer , eligible .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Taxotere</keyword>
</DOC>